RNeasy Mini Kit

High-quality total RNA in minutes.

Investigator 24plex QS Kit

Multiplex amplification for human ID, with CODIS and European standard markers.

QIAsphere

Monitor and manage your QIAsphere-ready instruments from anywhere, using any mobile device.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Find out more

QIAGENbioinformatics.com

COVID-19 testing and research

Up to date protocols and list of COVID-19 testing and research solutions.

RNeasy Mini Kit

High-quality total RNA in minutes.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QuantiFERON-TB Gold Plus

Detect TB infection with confidence.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Directors Dealings

Home  >  Investor Relations  >  Financial Reports & SEC Filings  >  Directors Dealings

QIAGEN publishes information on directors' dealings as reported to the company and pursuant to regulations by the United States Securities and Exchange Commission (SEC) and the Netherlands Authority for the Financial Markets (A-FM) pursuant to Section 2a Wmz 1996 and Art. 19. EU Directive No. 596/2014. Our insider trading policy can be downloaded as PDF document here.

Notes to the overview of recent transactions

* Cashless Exercise

1) According to a Rule 10b5-1 long-term Sales Plan ("Langzeitverkaufsvertrag").

2) Lawrence A. Rosen, Metin Colpan, Toralf Haag, Ross L. Levine, Elaine R. Mardis, Eva Pisa, Elizabeth E. Tallett, Stephen H. Rusckowski.

“Net share settlement” is done when a number of shares to cover expenses related to the grant release (such as taxes and transaction costs) are withheld by the Company.

Recent Transactions

Name and function Date and type Financial instrument Amount of shares SEC BAFin A-FM

Thierry Bernard,

Managing Director

03/31/24

Common Shares received through release of Performance Based Stock Units (“net share settlement”)

28,848

 

PDF PDF

Roland Sackers,

Managing Director

03/31/24

Common Shares received through release of Performance Based Stock Units (“net share settlement”)

57,268

 

PDF PDF

Thierry Bernard,

Managing Director

03/15/24

Common Shares received through release of Performance Based Stock Units (“net share settlement”)

5,487

 

PDF PDF

Roland Sackers,

Managing Director

03/15/24

Common Shares received through release of Performance Based Stock Units (“net share settlement”)

5,937

 

PDF PDF

All Supervisory,

Board Directors2)

02/29/24
Grant

Restricted Stock Units

7,056

 

PDF PDF

Thierry Bernard,

Managing Director

02/29/24
Grant

Performance Based Stock Units

128,535

 

PDF PDF

Roland Sackers,

Managing Director

02/29/24
Grant

Performance Based Stock Units

74,439

 

PDF PDF

Lawrence A. Rosen,

Supervisory Director

02/28/24

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

2,959

 

PDF PDF

Metin Colpan,

Supervisory Director

02/28/24

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

2,813

 

PDF PDF

Ross L. Levine,

Supervisory Director

02/28/24

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

2,560

 

PDF PDF

Elaine R. Mardis,

Supervisory Director

02/28/24

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

2,683

 

PDF PDF

Elizabeth E. Tallett,

Supervisory Director

02/28/24

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

2,987

 

PDF PDF

Thierry Bernard,

Managing Director

02/28/24

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

6,138

 

PDF PDF

Roland Sackers,

Managing Director

02/28/24

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

6,061

 

PDF PDF

Lawrence A. Rosen,

Supervisory Director

02/26/24

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

1,552

 

PDF PDF

Metin Colpan,

Supervisory Director

02/26/24

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

1,503

 

PDF PDF

Toralf Haag,

Supervisory Director

02/26/24

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

1,945

 

PDF PDF

Ross L. Levine,

Supervisory Director

02/26/24

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

1,385

 

PDF PDF

Elaine R. Mardis,

Supervisory Director

02/26/24

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

1,404

 

PDF PDF

Elizabeth E. Tallett,

Supervisory Director

02/26/24

Common Shares

received through release of Restricted Stock Units (“net share settlement”)

1,577

 

PDF PDF

Thierry Bernard,

Managing Director

02/21/24

Common Shares

received through release of Performance Based Stock Units (“net share settlement”)

11,048

-

PDF PDF

Roland Sackers,

Managing Director

02/21/24

Common Shares

received through release of Performance Based Stock Units (“net share settlement”)

33,898

-

PDF PDF